{"id":"hpc-cord-blood","safety":{"commonSideEffects":[{"rate":null,"effect":"Graft-versus-host disease (acute)"},{"rate":null,"effect":"Graft-versus-host disease (chronic)"},{"rate":null,"effect":"Graft failure or delayed engraftment"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hemorrhage"},{"rate":null,"effect":"Organ toxicity"}]},"_chembl":null,"_dailymed":{"setId":"df5c4e20-fc58-4b22-95f5-7d981708f587","title":"HPC, CORD BLOOD INJECTION [BLOODWORKS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cord blood-derived hematopoietic progenitor cells are infused to replace damaged or diseased bone marrow following myeloablative conditioning. These cells home to the bone marrow microenvironment, self-renew, and differentiate into all blood cell lineages, restoring hematopoietic function and immune reconstitution. Cord blood grafts offer advantages including reduced HLA matching requirements, lower graft-versus-host disease risk, and rapid availability from cryopreserved inventory.","oneSentence":"HPC (hematopoietic progenitor cells) from umbilical cord blood engraft in the bone marrow and reconstitute the hematopoietic and immune systems.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:09:00.541Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute leukemia in remission"},{"name":"Chronic leukemia"},{"name":"Myelodysplastic syndrome"},{"name":"Lymphoma"},{"name":"Multiple myeloma"},{"name":"Severe aplastic anemia"},{"name":"Inherited metabolic disorders"},{"name":"Inherited immunodeficiencies"}]},"trialDetails":[{"nctId":"NCT07332338","phase":"","title":"Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition","status":"AVAILABLE","sponsor":"StemCyte, Inc.","startDate":"","conditions":"Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome","enrollment":""},{"nctId":"NCT07184385","phase":"PHASE3","title":"A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition","status":"NOT_YET_RECRUITING","sponsor":"StemCyte, Inc.","startDate":"2026-03-31","conditions":"Long COVID, Post-COVID-19 Condition, Post-COVID Syndrome","enrollment":60},{"nctId":"NCT05682560","phase":"PHASE2","title":"Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome","status":"COMPLETED","sponsor":"StemCyte, Inc.","startDate":"2023-05-04","conditions":"Long COVID, Post-COVID Syndrome, Post COVID-19 Condition","enrollment":30},{"nctId":"NCT03735277","phase":"PHASE1","title":"Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"BHI Therapeutic Sciences","startDate":"2021-03-06","conditions":"Acute Ischemic Stroke","enrollment":10},{"nctId":"NCT00737516","phase":"PHASE2","title":"Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation","status":"COMPLETED","sponsor":"National Marrow Donor Program","startDate":"2000-01","conditions":"Leukemia, Lymphoma, Myelodysplastic Syndromes","enrollment":3621}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":185,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Allogeneic umbilical cord blood, hematopoietic stem cells"],"phase":"marketed","status":"active","brandName":"HPC, Cord Blood","genericName":"HPC, Cord Blood","companyName":"National Marrow Donor Program","companyId":"national-marrow-donor-program","modality":"Biologic","firstApprovalDate":"","aiSummary":"HPC (hematopoietic progenitor cells) from umbilical cord blood engraft in the bone marrow and reconstitute the hematopoietic and immune systems. Used for Acute leukemia in remission, Chronic leukemia, Myelodysplastic syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}